论文部分内容阅读
目的:分析我院内分泌糖尿病患者调脂药物的使用情况,并针对各药物类型的适用性进行比较分析,为临床用药提供借鉴。方法 :对我院内分泌科2014使用调脂药物的品种、数量、用法用量、不良反应等情况分析。结果 :2014年我院所用调脂药物中他汀类药物用量最高,其次为瑞舒伐他汀以及阿托伐他汀,占据比例分别为32.9%和32.3%;内分泌科使用的药物主要以阿托伐他汀(立普妥)以及非诺贝特为主,但是然他汀类药物的使用量仅占据9.0%,非诺贝特和多甘烷醇的比例分别为43.7%、36.8%;2014年内分泌科病区糖尿病患者使用的药物中他汀类药物比例最高,为75.2%,调脂药物比例为38.3%,联合用药患者占据比例为16.9%,但是有60.3%患者不能采用联合用药方针;随机抽取我院400例使用调脂药物的糖尿病患者进行调查,其中25.8%的血脂正常,但是应用多甘烷醇和非诺贝特的患者大多为高血脂患者;他汀类药物使用中48.7%患者晚上给药,但是有68.7%服用非诺贝特的患者每天晚上给药1次。结论 :我院调脂药物使用药物基本以他汀类为主,内分泌科使用各类调脂药物数量比较分散,糖尿病患者多数联合用药不适宜的情况需要予以调整,并且药物的服用时间也需要加以调整。
Objective: To analyze the usage of lipid-lowering drugs in patients with endocrine diabetes mellitus in our hospital and to compare the applicability of each drug type to provide reference for clinical use. Methods: Analysis of the variety, quantity, usage and dosage, and adverse reactions of the lipid-lowering drugs used in the Department of Endocrinology 2014 in our hospital. Results: The dosage of statins used in our hospital was the highest in 2014, followed by rosuvastatin and atorvastatin, accounting for 32.9% and 32.3% respectively. The drugs used in endocrinology were mainly atorvastatin (Lipitor) and fenofibrate, but the use of statins accounted for only 9.0%, fenofibrate and polyglycool were 43.7%, 36.8% respectively; Endocrinology 2014 District diabetes drugs used in patients with the highest proportion of statins, was 75.2%, lipid-lowering drugs accounted for 38.3%, combined medication accounted for 16.9% of patients, but 60.3% of patients can not use the combination of guidelines; randomly selected 400 Patients with diabetics using lipid-lowering drugs were investigated, with 25.8% of whom had normal lipids, but those who used polyglycolate and fenofibrate were mostly hypercholesterolemic; 48.7% of patients on statin use were given at night but 68.7% of patients taking fenofibrate were given once night at night. Conclusions: The main drugs for lipid-lowering drugs in our hospital are mainly statins. The quantity of various lipid-lowering drugs used in the endocrinology department is relatively dispersed. The inappropriate combination of most patients with diabetes needs to be adjusted, and the taking time of the drugs needs to be adjusted .